Nemaura Receives CE Mark Approval of SugarBEAT

- May 29th, 2019

Nemaura Medical (NASDAQ:NMRD) has announced it has received CE Mark approval for SugarBEAT, a non-invasive device for diabetics and pre-diabetics. As quoted in the press release: With this Approval, Nemaura is permitted to commence sales of SugarBEAT® throughout the European Union. Key Highlights: SugarBEAT® consists of a non-invasive, needle-free, disposable adhesive skin-patch connected to a … Continued

Nemaura Medical (NASDAQ:NMRD) has announced it has received CE Mark approval for SugarBEAT, a non-invasive device for diabetics and pre-diabetics.

As quoted in the press release:

With this Approval, Nemaura is permitted to commence sales of SugarBEAT® throughout the European Union.

Key Highlights:

  • SugarBEAT® consists of a non-invasive, needle-free, disposable adhesive skin-patch connected to a rechargeable transmitter
  • Lowest priced CGM in the industry
  • Enables users to spend more time in range (TIR) by providing an ambulatory glucose profile (AGP) chart
  • Targeting $179 billion global market opportunity including insulin and non-insulin dependent diabetics, pre-diabetics, and wearable health-tech markets
  • On track to submit U.S. Food and Drug Administration (FDA) application in mid-2019
  • Dedicated SugarBEAT® Symposia planned for the European Association for the Study of Diabetes (EASD) Barcelona Congress in September 2019, where key opinion leader data and end-user feedback are to be presented
  • CE Mark approval issued by British Standards Institute (BSI), including newly added predictive alert and alarm functionality
  • Product launch in United Kingdom and Germany planned for next quarter
  • Dr. Fred Schaebsdau, former General Manager of Dexcom Germany, to advise on SugarBEAT® launch

Dr. Faz Chowdhury, CEO of Nemaura, said, “We are very pleased to report CE Mark approval in Europe for SugarBEAT®, which is the world’s first non-invasive, needle-free, continuous glucose monitor (CGM).  Importantly, as a daily disposable adhesive skin-patch that sits on the surface of the skin, SugarBEAT® is painless, and versatile in terms of wear time. Given these benefits, we look forward to aggressively entering both the multi-billion-dollar diabetic (insulin and non-insulin dependent) and pre-diabetic markets.  In addition, we plan to target the wearable health tech market for health-conscious consumers, which is experiencing explosive growth. Due to the non-invasive nature of the sensor patch and connection to a rechargeable transmitter, SugarBEAT® will allow users the freedom to decide when, and for how long to wear the patch. Moreover, we have a unique competitive advantage, which we believe will make SugarBEAT® the lowest priced CGM device in the industry.  SugarBEAT® is protected by a solid IP portfolio with over 30 issued and pending patents across multiple patent families.”

Click here to read the full press release.

Read our new 2019 medical device report today

 

 

Including: 3+ stocks to watch as well as valuable market data   Get My Free Report Click here to download for free

 

Leave a Reply

Your email address will not be published. Required fields are marked *